INOZYME PHARMA INC (INZY) Stock Price, Quote, News and Overview
NASDAQ:INZY - Nasdaq - US45790W1080 - Common Stock - Currency: USD
INZY Quote, Performance and Key Statistics
1.49
-0.13 (-8.02%)
The current stock price of INZY is 1.49 USD. In the past month the price increased by 81.44%. In the past year, price decreased by -67.18%.
INZY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.09 | 346.84B | ||
| AMGN | AMGEN INC | 13.49 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1724.79 | 128.59B | ||
| GILD | GILEAD SCIENCES INC | 13.28 | 128.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.62 | 65.17B | ||
| ARGX | ARGENX SE - ADR | 345.61 | 40.09B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.40B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 21.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.81B | ||
| BIIB | BIOGEN INC | 7.7 | 17.85B |
Related stock screener links
About INZY
Company Profile
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The firm is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The firm also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
Company Info
INOZYME PHARMA INC
321 Summer Street, Suite 400
Boston MASSACHUSETTS 02210 US
CEO: Axel Bolte
Employees: 67
Phone: 18573304340
INOZYME PHARMA INC / INZY FAQ
What is the stock price of INOZYME PHARMA INC today?
The current stock price of INZY is 1.49 USD. The price decreased by -8.02% in the last trading session.
What is the ticker symbol for INOZYME PHARMA INC stock?
The exchange symbol of INOZYME PHARMA INC is INZY and it is listed on the Nasdaq exchange.
On which exchange is INZY stock listed?
INZY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INOZYME PHARMA INC stock?
15 analysts have analysed INZY and the average price target is 13.77 USD. This implies a price increase of 824.16% is expected in the next year compared to the current price of 1.49. Check the INOZYME PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INOZYME PHARMA INC worth?
INOZYME PHARMA INC (INZY) has a market capitalization of 96.19M USD. This makes INZY a Micro Cap stock.
How many employees does INOZYME PHARMA INC have?
INOZYME PHARMA INC (INZY) currently has 67 employees.
What are the support and resistance levels for INOZYME PHARMA INC (INZY) stock?
INOZYME PHARMA INC (INZY) has a resistance level at 1.63. Check the full technical report for a detailed analysis of INZY support and resistance levels.
Should I buy INOZYME PHARMA INC (INZY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INZY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INZY, evaluating the profitability, health, valuation and growth aspects
- INOZYME PHARMA INC (INZY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INOZYME PHARMA INC (INZY) Sales and EPS estimates to see what analysts future expectations are.
- INOZYME PHARMA INC (INZY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INOZYME PHARMA INC (INZY) Insider and Institutional Ownership to learn about the owners and their transactions.
- INOZYME PHARMA INC (INZY) Stock Chart to make your own analysis
- INOZYME PHARMA INC (INZY) Latest news and press-releases to stay up to date.
Does INOZYME PHARMA INC (INZY) stock pay dividends?
INZY does not pay a dividend.
When does INOZYME PHARMA INC (INZY) report earnings?
INOZYME PHARMA INC (INZY) will report earnings on 2025-05-13, before the market open.
What is the Price/Earnings (PE) ratio of INOZYME PHARMA INC (INZY)?
INOZYME PHARMA INC (INZY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.62).
What is the Short Interest ratio of INOZYME PHARMA INC (INZY) stock?
The outstanding short interest for INOZYME PHARMA INC (INZY) is 7% of its float. Check the ownership tab for more information on the INZY short interest.
INZY Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to INZY. When comparing the yearly performance of all stocks, INZY is a bad performer in the overall market: 86.26% of all stocks are doing better.
INZY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INZY. INZY may be in some trouble as it scores bad on both profitability and health.
INZY Financial Highlights
Over the last trailing twelve months INZY reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS decreased by -18.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.82% | ||
| ROE | -176.43% | ||
| Debt/Equity | 0.54 |
INZY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to INZY. The Buy consensus is the average rating of analysts ratings from 15 analysts.